Status:
COMPLETED
Efficacy of Botulinum Toxin Type A for Acute Acquired Comitant Esotropia: An Age-Stratified Two-Year Follow-Up Study
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Acute Acquired Comitant Esotropia
Eligibility:
All Genders
Phase:
NA
Brief Summary
The goal of this clinical trial is to assess and compare the efficacy of two-year follow-up botulinum toxin type A （BTXA) in the treatment of acute acquired comitant esotropia (AACE) across five age g...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute acquired comitant esotropia (AACE) with sudden onset and diplopia
- Normal eye movements with deviation difference ≤5 prism diopters (PD) in all gaze directions
- Hyperopia \< +3.00 diopters
- \<10 PD reduction in esotropia with hypermetropic spectacle correction
- No prior extraocular muscle surgery
- Absence of congenital/developmental anomalies affecting treatment outcomes
Exclusion
- Deviation difference \>5 PD in any gaze direction
- Hyperopia ≥ +3.00 diopters
- History of extraocular muscle surgery
- Presence of congenital/developmental anomalies potentially impacting outcomes
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
276 Patients enrolled
Trial Details
Trial ID
NCT06966999
Start Date
January 1 2019
End Date
June 1 2023
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000